Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 10/20 | 0.61 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29720772 | 0.99 | ACVRL1 (0.60) | ACVRL1PLATTYRO3PIK3CDMTOR | |
| Hydrochloric Acid SCHEMBL19377754 | 0.99 | ACVRL1 (0.60) | ACVRL1PLATTYRO3PIK3CDMTOR | |
| SCHEMBL31391141 | 0.90 | ACVRL1 (0.49) | ACVRL1TYRO3PIK3CDMTORRICTOR | |
| SCHEMBL16011301 | 0.83 | ACVRL1 (0.58) | ACVRL1TYRO3PIK3CDMTORRICTOR | |
| SCHEMBL19429526 | 0.83 | ACVRL1 (0.45) | ACVRL1PIK3CDMTORRICTORRPTOR | |
| SCHEMBL16011302 | 0.83 | ACVRL1 (0.58) | ACVRL1TYRO3PIK3CDMTORRICTOR | |
| SCHEMBL19377805 | 0.83 | PIK3CD (0.53) | ACVRL1TYRO3PIK3CD | |
| SCHEMBL23834529 | 0.82 | ACVRL1 (0.43) | ACVRL1TYRO3PIK3CDMTORRICTOR | |
| SCHEMBL19377710 | 0.82 | ACVRL1 (0.44) | ACVRL1TYRO3PIK3CDMTORRICTOR | |
| SCHEMBL19377514 | 0.80 | TYRO3 (0.44) | ACVRL1TYRO3PIK3CDMTORRICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | claimed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534479-B2 | Triazine compound and composition and use thereof | FINDCURE BIOSCIENCES (ZHONGSHAN) CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | BEIJING FINDCURE BIOSCIENCES, LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-3436461-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-11-15 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | ACVRL1 1370/4885PLAT 1920/4885TYRO3 96/4885 |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | ACVRL1 1161/4885PLAT 1604/4885TYRO3 106/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | ACVRL1 1161/4885PLAT 1604/4885TYRO3 106/4885 |
| US-12534479-B2 | Triazine compound and composition and use thereof | JAK1, CCR1, PEAK1 | ACVRL1 1619/4885PLAT 4792/4885TYRO3 456/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | ACVRL1 1161/4885PLAT 1604/4885TYRO3 106/4885 |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | JAK1, MAP3K5, MAP3K15 | ACVRL1 1152/4885PLAT 3822/4885TYRO3 115/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | ACVRL1 1161/4885PLAT 1604/4885TYRO3 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.